STOCKSNeurocrine Biosciences Leads Pre-Market Biotech MoversBy Alicia McElhaneyApr 12, 2017 9:32 AM EDT
STOCKSBiotech Movers Trading Positive Ahead of Market's OpenBy Alicia McElhaneyApr 11, 2017 9:30 AM EDT
STOCKSMedivation Founder Takes Helm at Axovant, Shares SpikeBy Alicia McElhaneyApr 10, 2017 10:00 AM EDT
STOCKSEndo international, AngioDynamics Lead Biotech MoversBy Alicia McElhaneyApr 7, 2017 9:25 AM EDT
MERGERS AND ACQUISITIONSDollar Store Debacle Bodes Poorly for Walgreens-Rite Aid MergerBy Alicia McElhaneyApr 6, 2017 11:33 AM EDT
STOCKSValeant Shares Close Below $10 for First Time Since 2008By Alicia McElhaneyApr 5, 2017 4:03 PM EDT
STOCKSValeant Plummets After Revealing Jaw-Dropping Payday for Its CEOBy Alicia McElhaneyApr 4, 2017 1:55 PM EDT
MERGERS AND ACQUISITIONSAfter Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals ReuniteBy Alicia McElhaneyApr 2, 2017 5:40 PM EDT
HEALTHHere Are Some of the Top Healthcare Stocks in the First QuarterBy Alicia McElhaneyMar 31, 2017 8:30 PM EDT
STOCKSMylan Hires Former SEC Commissioner for Chief Legal Officer PositionBy Alicia McElhaneyMar 28, 2017 3:35 PM EDT
MERGERS AND ACQUISITIONSMylan Hit After Abbott Dumps SharesBy Alicia McElhaneyMar 24, 2017 11:41 AM EDT
STOCKSHere's How to Invest in Hospital Stocks Ahead of AHCA VoteBy Alicia McElhaneyMar 24, 2017 10:27 AM EDT
MERGERS AND ACQUISITIONSA Deal is Imminent For Depomed, CFO SaysBy Alicia McElhaneyMar 23, 2017 7:07 PM EDT
MERGERS AND ACQUISITIONSCan Abbott Outperform Despite Alere?By Alicia McElhaneyMar 22, 2017 2:47 PM EDT
STOCKSRegenxbio Leads Biotech Movers Ahead of Market's OpenBy Alicia McElhaneyMar 22, 2017 9:31 AM EDT
REGULATIONMylan's Government Connections Go Deeper Than Initially BelievedBy Alicia McElhaneyMar 21, 2017 9:06 AM EDT
MERGERS AND ACQUISITIONSFred's Appoints Retail-Focused Board Members As Walgreens and Rite Aid Near FTC ApprovalBy Alicia McElhaneyMar 16, 2017 10:12 PM EDT
STOCKSValeant Shares Skyrocket After Hours on ValueAct BuyBy Alicia McElhaneyMar 16, 2017 5:05 PM EDT
STOCKSHealth Care Investors Attempt to Parse Trump BudgetBy Alicia McElhaneyMar 16, 2017 10:25 AM EDT
STOCKSImmunomedics Soars on Injunction Against Seattle Genetics DealBy Alicia McElhaneyMar 9, 2017 1:33 PM EST
STOCKSValeant Launches Loan Offering Days After Paying Down $1.1 Billion in DebtBy Alicia McElhaneyMar 9, 2017 12:17 PM EST
STOCKSPoliticians Question EpiPen Competitor Auvi-Q's High PricetagBy Alicia McElhaneyMar 8, 2017 5:17 PM EST
STOCKSHere's Why Weight Watchers' New CEO Should Be a WomanBy Alicia McElhaneyMar 8, 2017 2:39 PM EST
CORPORATE GOVERNANCECan Mylan Shake Specter of Poor Corporate Governance?By Alicia McElhaneyMar 3, 2017 6:07 PM EST
MERGERS AND ACQUISITIONSKite Completes Additional Public OfferingBy Alicia McElhaneyMar 2, 2017 2:00 PM EST
STOCKSTwenty More States Accuse Mylan, Teva and Others of Price CollusionBy Alicia McElhaneyMar 1, 2017 4:53 PM EST
STOCKSValeant Shares Plummet After Reporting 13% Drop In SalesBy Alicia McElhaneyFeb 28, 2017 4:13 PM EST
STOCKSBiotech Movers: Cempra flys high on phase three resultsBy Alicia McElhaneyFeb 24, 2017 9:38 AM EST
